Structural Requirements for in Vivo Myosin I Function in Aspergillus nidulans*

(Received for publication, June 1, 1998, and in revised form, July 30, 1998)

Nir Osherov‡, Roxanne A. Yamashita‡, Yun-Shin Chung, and Gregory S. May§

From the Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030

We have investigated the minimal requirements of the tail region for myosin I function in vivo using the filamentous fungus Aspergillus nidulans. The CL3 strain (McGoldrick, C. A., Gruver, C., and May, G. S. (1995) J. Cell Biol. 128, 577–587) was transformed with a variety of myoA constructs containing mutations in the IQ, TH-1-like, SH3, and proline-rich domains by frameshift or in-frame deletions of the tail domains. The resulting strains contained wild type myoA driven by the alcA promoter and a mutant myoA driven by its endogenous promoter. This strategy allowed for selective expression of the wild type and/or mutant form of MYOA by the choice of growth medium. Proper septation and hyphal branching were found to be dependent on the interaction of the IQ motifs with calmodulin, as well as, the presence of its proline-rich domain. Additionally, a single proline-rich motif was sufficient for nearly wild type MYOA function. Most surprisingly, the SH3 domain was not essential for MYOA function. These studies expand our previous knowledge of the function of MYOA to include roles in hyphal morphogenesis, septal wall formation, and cell polarity, laying the groundwork for more detailed investigations on the function of the various tail domains in MYOA.

Class I myosins appear to be involved in a variety of cellular processes, including cell motility, contractile vacuole function, receptor-mediated endocytosis, protein secretion, maintenance of cytoskeletal organization, and intracellular organelle movement (1, 2). In addition to the highly conserved myosin motor domain, class I myosins possess variable tail regions. In general, the tail of class I myosins consists of the IQ light chain-binding domain, and the tail homology (TH)1, 2, and 3 domains. The TH-1 domain is rich in basic amino acids, binds to acidic phospholipids, and has an ATP insensitive actin-binding site. The TH-2 domain is rich in amino acids glycine, proline, and alanine or glycine, proline, and glutamine. The TH-3 domain is an SH3 domain (Src homology 3) (3). Class I myosins have been identified in many lower eukaryotes including Dictyostelium discoideum (4), Saccharomyces cerevisiae (5–7), Acanthamoeba castellani (8), and Aspergillus nidulans (9). Although class I myosins have been studied in a variety of systems, the elucidation of their function has been complicated by the presence of multiple class I myosins with apparently overlapping function, such that loss of any single myosin I and in some cases deletion of multiple myosins I is not lethal.

The discovery of myoA as an essential class I myosin in A. nidulans (9) allows us to address many aspects of MYOA function, including regulation by phosphorylation, protein interactions, and the functions of the specific domains present in the carboxyl terminus (COOH terminus). The amino-terminal motor domain contains an ATP-sensitive F-actin-binding site and provides the force required for movement along actin filaments. The COOH-terminal tail region of MYOA is composed of an IQ domain with two IQ motifs, a TH-1-like domain, an SH3 domain, and a proline/alanine-rich domain with 2 proline/alanine motifs (Fig. 1). The TH-1-like domain can be further subdivided into 2 subdomains. The first subdomain is rich in basic amino acids and the second subdomain is slightly proline-rich.

We previously showed that MYOA plays a role in secretion and polarized growth by the creation of a conditionally null myoA strain, CL3, in which the inducible alcohol dehydrogenase (alcA) promoter drives the expression of myoA (9). More recently, we demonstrated that MYOA functions in endocytosis by mutating the phosphorylation site serine 371 to glutamic acid and activating endocytosis (10). Here we investigate the structural requirements of the tail region of MYOA that are necessary for its function. Transformation of the CL3 strain with mutant forms of myoA under the control of its own promoter allows us to selectively maintain an otherwise lethal transformant for further study. The use of an inducible promoter to produce wild type MYOA and the endogenous myoA promoter to produce mutant MYOA allows for differential expression of either the wild type or mutant MYOA or both depending on the growth medium.

This paper addresses the in vivo significance of the four domains present in the COOH-terminal region of MYOA. We have chosen to mutate the tail domains of myoA because it is this portion of the polypeptide that leads to specific cellular localization and function. We have transformed six different mutant tail constructs corresponding to frameshift and deletion mutations and tested them for their ability to complement the conditional null phenotype of CL3. Additionally, we have characterized the phenotypes of the viable myoA frameshift and deletion mutants by examining the consequences of these changes on cell growth, cell morphology, protein secretion, and endocytosis.

MATERIALS AND METHODS

Strains, Media, and Growth Conditions—Construction of the CL3 strain was described previously (9). The yeast strain Y190 (MATa gal4Δ, gal80A, his3Δ200, trp1-901, ade2-101, ura3-52, leu2-3, 112, URA3::Gal–lacZ, LYS2::GAL(UAS)−HIS3, cyh−) was used for two-hybrid screens (11). The bacterial strain DH5αF+(F’ φ80lacZΔM15 ΔlacZYA-argF)U169 deoR recA1 endA1 hsdR17(rK−, mK+) supE44 λ−

* This work was supported by grants from the National Institutes of Health, NIGMS (to G. S. M.) and a National Institutes of Health training grant (to R. A. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ Contributed equally to the results of this work.
§ To whom all correspondence should be addressed: Dept. of Cell Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel.: 713–798–4756; Fax: 713–798–7799; E-mail: gsmary@bcm.tmc.edu.
The analysis was used to identify transformants containing a single inte-

**Table I**

| Strain         | Vector   | Marker       | Insert     |
|----------------|----------|--------------|------------|
| pGEMmyoAΔKpn1 | pGEMmyoA  | MYOA 1–744   |            |
| pGEMmyoAΔVho1 | pGEMmyoA  | MYOA 1–1126  |            |
| pGEMmyoAΔBamH1| pGEMmyoA  | MYOA 1–1155  |            |
| FSKpH1        | pGEMmyoA  | pyroA MYOA 1–744|
| FSKh1         | pGEMmyoA  | pyroA MYOA 1–1126|
| FSBamH1       | pGEMmyoA  | pyroA MYOA 1–1155|
| pBSKSA1Q      | pBlueScriptKS | MYOA1–730, 793–1160 |
| pBSKSA7H1-1ike| pBlueScriptKS | MYOA1–792, 1081–1160 |
| pBSKSA7SH3    | pBlueScriptKS | MYOA1–1080, 1131–1160 |
| pGEMmyoAΔΔQ   | pGEMmyoA  | MYOA1–730, 793–1160|
| pGEMmyoAΔΔTH-1like |pGEMmyoA   | MYOA1–730, 793–1160|
| pGEMmyoAΔΔSH3 | pGEMmyoA  | MYOA1–1080, 1131–1160|
| ΔQ            | pGEMmyoA  | pyroA MYOA 1–730, 793–1160|
| ΔTH-1-like    | pGEMmyoA  | pyroA MYOA 1–792, 1081–1160|
| ΔSH3          | pGEMmyoA  | pyroA MYOA 1–1080, 1131–1160|
| myoA49        | pUC19     | MYOA 731–1249|
| myoA10        | pAS2      | TRP1 MYOA 731–1249|
| myoA41        | pUC19     | MYOA 793–1249|
| myoA12        | pUC19     | MYOA 1081–1249|
| myoA13        | pAS2      | TRP1 MYOA 793–1249|
| myoA14        | pAS2      | MYOA 1081–1249|
| myoA18        | PRSETA    | MYOA 731–1249|
| myoA19        | PRSETA    | MYOA 793–1249|
| myoA20        | PRSETA    | MYOA 1081–1249|

Theoretical and computational analysis was used to identify transformants containing a single inte-

**Mutational Analysis of Class I Myosin Function**

**Table I**

**Strains, Vectors, Markers, and Inserts**

- **Strain**: pGEMmyoAΔKpn1, pGEMmyoAΔVho1, pGEMmyoAΔBamH1, FSKpH1, FSKh1, FSBamH1, pBSKSA1Q, pBSKSA7H1-1ike, pBSKSA7SH3, pGEMmyoAΔΔQ, pGEMmyoAΔΔTH-1like, pGEMmyoAΔΔSH3, ΔQ, ΔTH-1-like, and ΔSH3 (Table I).

- **Vector**: pGEMmyoA, pGEMmyoAΔΔQ, pGEMmyoAΔΔTH-1like, and pGEMmyoAΔΔSH3 were renamed CL3-WT, ΔQ, ΔTH-1-like, and ΔSH3 (Table I).

- **Marker**: pGEMmyoAΔΔQ, pGEMmyoAΔΔTH-1like, and pGEMmyoAΔΔSH3 were renamed CL3-WT, ΔQ, ΔTH-1-like, and ΔSH3 (Table I).

Plasmids containing the different frameshift or deletion mutations were transformed into CL3. Primary transformants were purified three times to single spots on selective MM-glycerol medium. Southern analysis was used to identify transformants containing a single inte-

**Growth Studies**—Induction or repression of the alcA promoter was demonstrated by plating the transformants on various carbon sources (9). Growth in YAG represses the alcA driven myoA and allows the endogenous myoA promoter to transcribe the mutated MYOA product, such that if the portion of the tail deleted is an essential region for myosin I function, a lethal phenotype would be expected. Growth on MM-glycerol medium induces the alcA driven myoA, such that wild type MYOA is produced and all strains will be viable and wild type for growth.

Hyphal growth studies were performed by plating 10^5–10^6 spores/ml onto sterile coverslips in YAG. At various time points a coverslip was removed randomly selected samples were chosen and recorded. The lengths of the germings were measured in microns. Recorded images were also analyzed for germination and branching morphology. Radial growth assays were performed by plating 2–3 colony forming units per plate on solid YAG as described previously (16).

**Two-hybrid Screen**—To make the bait plasmids an Ndel site was introduced by oligonucleotide-directed mutagenesis of the myoA cDNA (9).Frameshifting an in-frame methionine at amino acid positions 724, 792, or 1079 of the MYOA protein corresponding to the IQ, TH-1-like, and SH3 domains. The PCR fragments were then cloned into the Ndel and XbaI sites in pUC19 before being cloned into pAS2 as Ndel-Sall fragments. The A. nidulans activation domain library was constructed in pAD-GAL4 (Stratagene, La Jolla, CA) and was kindly provided by Dr. Osmani of the Geisenger Clinic, Weiss Center for Research, Danville, PA. The two-hybrid screen was conducted as described (11).

**Binding of MYOA to CaM-Sepharose**—The same cDNA fragments in pUC19 used to make the bait plasmids were cloned into PRSETA (Invitrogen, Carlsbad, CA) vector that had Ndel and HindIII sites. These plasmids were used in a linked in vitro transcription/translation reaction (PROTEINscript, Ambion, Inc., Austin, TX) and the translated product was used in a direct binding assay to CaM-Sepharose (P4385, Sigma) in 50 mM Tris-HCl, pH 8.0, 150 mM NaCl with 1 mM CaCl2 or with 1 mM EGTA. The CaM-Sepharose slurry was incubated with each of the translation products in the two buffers for 30 min at 4°C with gentle mixing. The CaM-Sepharose beads were washed three times with buffer and examined on 10% SDS-PAGE (17) with starting material as a control for amount of protein present. Following electrophoresis, proteins were stained with Coomassie Blue, dried, and exposed to x-ray film at ~70 °C.

**Genetic, Molecular Genetic and Other Methods**—Methods for the growth and genetic manipulation of A. nidulans have been described in detail elsewhere (12, 18). Similarly, those methods used in the manipulation of plasmids and molecular cloning have been described elsewhere (18).
RESULTS

Detection of the myoA Frameshift and Deletion Mutations in the Genome—It is the tail region of class I myosins that is thought to provide them with their specific cellular location and function. For this reason we began our mutational studies of class I myosin function in A. nidulans by creating frameshift and deletion mutants that would alter specific domains of the polypeptide. Our emphasis in these studies was on the highly conserved IQ, calmodulin binding motif, the SH3 domain, and the proline-rich region of the polypeptide. Genomic Southern analysis was performed on 15 purified transformants for each of the transforming plasmids. Genomic DNA digested with XhoI was probed with 3 different probes to identify integration into the myoA locus (Figs. 2 and 3). Approximately 70% of transformants had integrated a single copy of the mutant allele into the alcA activated full-length myoA locus, and these were discarded because of the probability of interallelic recombination between the mutant and wild type tail domains. Only 20% of the transformants had integrated a single copy of the mutant allele into the shorter myoA locus (Figs. 2 and 3). These were selected for further study. Surprisingly, the TH-1-like mutant integrated only into the alcA-myoA gene, so these transformants were mapped to verify that recombination had not occurred between wild type and mutant alleles and selected for further study (Fig. 3, lane 7). The phenotypes of the frameshift and deletion mutations were confirmed for at least three independent isolates.

The Mutant MYOA Proteins Are Detected by Western Blotting—Mutant strains were grown on MM-glycerol medium so that both the wild type MYOA protein, whose synthesis was driven by the alcA promoter and the mutant MYOA protein made from the myoA promoter were expressed. In addition, viable mutant strains were grown on rich YAG medium to repress expression of the wild type protein. The CL3 and CL3-WT transformant control strains (Fig. 4) demonstrate that under repressing growth conditions (Fig. 4, lanes labeled Y) CL3 expresses barely detectable levels of wild type MYOA. The results indicate that the mutant proteins are expressed for the FSBamHI, ΔIQ, ΔTH-1-like, and ΔSH3 strains (lanes labeled Y

| Primer | Sequence |
|--------|----------|
| myoA4  | GAACCATTAAGCCTA |
| T3     | ATTACCCCTCCTAGAAAG |
| IQ-1   | GAGGCTATTAGCGACCCGGCCCTTTGCTTCTGACACGTTT |
| IQ-2   | GAACCGTCGAGAACCAAGGGCGGTCGCGCATAGCCTC |
| TH-1-like-1 | CGTACGAGAACAGCTGCCTTTAGCCTCAGC |
| TH-1-like-2 | GCTGAACTGTCAGGCAGACCAGTCATTCCTCCTACAG |
| SH3-1   | GAGGGCGAAGAAAGAAAAGGAGGAGCAAGCTTGCACAGTCAGC |
| SH3-2   | GGGTGCAACTTGGCTTCTTTCCTTCTGCTTCTGTTT |

TABLE II

Oligonucleotides used in these studies and their sequences

| Primer | Sequence |
|--------|----------|
| myoA4  | GAACCATTAAGCCTA |
| T3     | ATTACCCCTCCTAGAAAG |
| IQ-1   | GAGGCTATTAGCGACCCGGCCCTTTGCTTCTGACACGTTT |
| IQ-2   | GAACCGTCGAGAACCAAGGGCGGTCGCGCATAGCCTC |
| TH-1-like-1 | CGTACGAGAACAGCTGCCTTTAGCCTCAGC |
| TH-1-like-2 | GCTGAACTGTCAGGCAGACCAGTCATTCCTCCTACAG |
| SH3-1   | GAGGGCGAAGAAAGAAAAGGAGGAGCAAGCTTGCACAGTCAGC |
| SH3-2   | GGGTGCAACTTGGCTTCTTTCCTTCTGCTTCTGTTT |

TABLE III

Oligonucleotide primer pairs and the templates used to make the PCR products in the construction of the MYOA deletion mutants

| Template | Primer pairs | Predicted size |
|----------|--------------|----------------|
| pBKS SpeI-BamHI | IQ-1/T3 | 1100 bp |
| pBKS SpeI-BamHI | myoA4/IQ-2 | 330 bp |
| pBKS SpeI-BamHI | TH-1-like-1/T3 | 240 bp |
| pBKS SpeI-BamHI | myoA4/TH-1-like-2 | 600 bp |
| pBKS SpeI-BamHI | SH3-1/T3 | 80 bp |
| pBKS SpeI-BamHI | myoA4/SH3-2 | 1300 bp |
| IQ PCR products | myoA4/T3 | 1400 bp |
| TH-1-like PCR products | myoA4/T3 | 770 bp |
| SH3 PCR products | myoA4/T3 | 1470 bp |
sign of spore germination is spore swelling at about 2 h of growth; where the first germ tube emerged. After 11 to 12 h of growth, apical extension. Between 8 and 10 h of growth a second germ tube emerged. There is then a period of rapid hyphal growth by hyphal branching, and septation are precisely controlled events (Table IV). The differential growth effect for the mutants on YAG is characterized by our antibody. Protein loaded on each lane was approximately equal as demonstrated by a nonspecific lower molecular weight band (labeled NS) present in every lane. Growth Characteristics of the FSXhoI, FSBamHI, ΔIQ, and ΔSH3 Mutants—We examined the growth of control and mutant strains on solid and liquid media to assess the phenotypes of the various myoA mutations used in this study. Growth was assessed on liquid as well as solid media because we previously have seen defects in submerged culture not seen on solid media (10). Growth of the mutant strains, a wild type myoA control transformant, and the parental CL3 strain was tested on solid YAG and MMV-glycerol plates to determine the effect of the mutations on their ability to form a colony (Fig. 5). As expected for recessive mutations, all the strains exhibited wild type growth on MMV-glycerol medium because as shown by Western blotting, both the mutant and wild type MYOA proteins were made when the fungus is grown on this medium (Fig. 5, A and B). On YAG medium the FSBamHI and ΔSH3 strains appeared to grow as well as the wild type control and in quantitative growth studies, we found the FSBamHI and ΔSH3 strains produced colonies that were 86 and 86%, respectively, of the CL3-WT strain in diameter. In contrast, the ΔIQ and FSXhoI mutants formed very small colonies on YAG (Fig. 5, c and d), while the FSKpn1 and ΔTH-1-like mutants did not grow at all. The differential growth effect for the mutants on YAG is because the alcA promoter is repressed, thus allowing only the mutant form of MYOA to be expressed. We next examined the growth of the control and mutant strains in submerged culture. The processes of spore germination, germ tube emergence, hyphal branching, and septation are precisely controlled events in A. nidulans (19, 20). For wild type strains the first visible sign of spore germination is spore swelling at about 2 h of growth, followed by germ tube emergence at 5–7 h (Table IV and Fig. 6). There is then a period of rapid hyphal growth by apical extension. Between 8 and 10 h of growth a second germ tube emerges from the swollen spore on the side opposite of where the first germ tube emerged. After 11 to 12 h of growth, hyphal branches begin to appear from the subapical compartments of the growing mycelium. With these observations as our baseline, we assessed each of the mutants for defects in these processes (Table IV, Fig. 6). The FSBamHI and ΔSH3 mutant strains begin to germinate at 6–7 h with only a slight delay in reaching the maximum compared with the wild type control and hyphal elongation was at a rate similar to that of the control strain (Fig. 6). In contrast, the ΔIQ and FSXhoI mutants germinate much later, only after 10 or more hours in culture and their rate of hyphal growth is greatly reduced (Fig. 6). During the first 8 h of growth the ΔIQ and FSXhoI mutants display only isotropic growth like that seen for the parental CL3 strain (Fig. 7). In contrast, the control, ΔSH3, and FSBamHI mutant strains all germinated (80–90% of the spores, Table IV) and extended germ tubes that produced normal hyphae (Fig. 7). The viable mutants all displayed reduced hyphal growth rates compared with controls in submerged cultures. The ΔIQ mutant displayed the slowest rate of hyphal elongation at 16% of the wild type rate. The FSXhoI had a hyphal growth rate that was 36% of wild type. The FSBamHI and ΔSH3 mutants had hyphal growth rates that were 64 and 54% of that of the wild type rate, respectively. Thus, while these two mutants display only slightly reduced rates of radial growth on plates they grew significantly slower in submerged culture, like we previously saw for other myoA mutations (10). The FSXhoI and ΔSH3 Mutants Have Defects in Septation and Hyphal Morphogenesis—We examined the growth of the ΔIQ and the FSXhoI mutant strains in greater detail because of their dramatic growth defects (Fig. 8). The ΔIQ mutant strain began germination after 9–10 h, approximately 3–4 h later than the CL3-WT strain. In 5–10% of the population, ΔIQ more than one germ tube emerged and in some cases up to 5 germ tubes appeared simultaneously from the swollen spore. Furthermore, in 90% of the germlings a second germ tube appeared at an odd angle, instead of emerging on the side opposite the first germ tube as in the wild type control. The ΔIQ mutant strain produced hyphae that were contorted and kinked with visibly thickened cell walls. The average diameter of the hyphae was approximately twice that of the control strain (Table V). Multiple hyphal branches from a single subapical compartment were frequently observed and the branches were perpendicularly rather than the acute angle seen in the wild type. Septa were also irregularly spaced and were often formed at odd angles (Fig. 8). Septa were placed every 16 ± 7 μm compared with the 39 ± 5 μm in the wild type control hyphae (Table V). The FSXhoI mutant began germinating after 10 h, nearly 5 h
after CL3-WT. FSXhoI germlings display aberrant hyphal branching pattern that is distinct from the hyphal branching defects seen in the ΔIQ mutant. In the FSXhoI mutant Y-shaped apical compartments (Fig. 8) characterize the hyphal branching defect. Branches in the apical compartment of wild type hyphae are never observed. Hyphal and septal morphology are structurally normal in this mutant (Fig. 8), although the positioning of septa is abnormal. Septa were spaced every 18 ± 6 μm in the FSXhoI mutant compared with 39 ± 5 μm in the control strain (Table V).

Decreased Levels of Wild Type MYOA Results in Phenotypic Growth Defects That Are Distinct from the Mutant Strains—There are two ways to explain the spectrum of phenotypes found in the MYOA tail domain mutants. The first is that they simply reflect the general level of activity of each mutant MYOA, from inactive (FSKpn1, ΔTH-1-like) through partially active (ΔIQ, FSXhoI) to almost normal (ΔSH3 and FS BamH1).

The second is that the phenotype of each mutant reflects a subset of defects correlating with the specific role of the deleted domain, thereby providing us with insight into their function. In order to test these hypotheses, wild type MYOA was expressed at different levels in the CL3 strain, and the phenotypes were examined in detail. Expression of MYOA under the control of the alcA promoter can be controlled in the CL3 strain by the choice of the growth medium (9). The CL3 strain was grown on repressing medium (YAG), semi-repressing medium (MM-glucose), and nonrepressing, noninducing medium (MM-glycerol) to assess the in vivo effects of the levels of MYOA expression on the growth of the fungus. Previously, a Western blot of the CL3 strain grown on the various carbon sources and probed with an affinity purified MYOA antibody was used to demonstrate that growth on these different media resulted in differing levels of MYOA (9) and these differing levels give rise to different phenotypes (Fig. 9). On YAG little or no MYOA is being expressed and results in isotropic growth. On MM-glucose small quantities of MYOA are produced resulting in initial isotropic growth, thickened cell walls, perpendicular hyphal branching, decreased septal spacing, and swellings throughout the germ tube and septal walls. In contrast, the FSXhoI mutant displays a very different phenotype, with normal cell wall thickness, septal compartments that are shorter and septal walls that are perpendicular to the hyphal compartments. The ΔIQ mutant differs from the CL3 on MM-glucose in that its septa are not perpendicular to the germ tube and they are present more frequently. We concluded therefore that the phenotypes of the tail domain mutants do not simply reflect the levels of functional MYOA present and provide us with insights into how the different domains contribute to MYOA function in vivo.

CaM Binds to the IQ Motif of MYOA—As a means of understanding why the deletion of the IQ domain or the proline-rich domain was deleterious to the growth of the fungus, we undertook a study to identify proteins that interact with the tail region of MYOA. Using the entire tail region of MYOA as bait, we isolated 82 positive clones that interacted with the tail region of MYOA. All but one of these MYOA interacting clones encoded calmodulin (CaM). It had been shown previously that CaM or other EF-hand proteins serve as the light chain for class I myosins (1, 2). None of the CaM encoding clones were positive in the two-hybrid analysis with bait clones pnyoA13 and pnyoA14 (Table I) that lacked the IQ motifs, implicating the IQ motifs for the site of interaction for CaM. The same coding regions were cloned into PRSETA generating pnyoA18, pnyoA 19, and
myoA20 (Table III) for in vitro transcription and translation. The products of the reaction were used for CaM-Sepharose affinity chromatography. Only the longest protein containing the IQ motifs bound to CaM-Sepharose in the presence of EGTA and Ca$^{2+}$ (Fig. 10, pmyoA18 lanes). Both the two-hybrid system and the CaM-Sepharose binding assay mapped the CaM-binding site to a 62-amino acid region that consists of a known CaM-binding structure, the IQ motif.

**DISCUSSION**

Our experiments address the in vivo structural requirements of the tail region of the class I myosin, MYOA. The mutations we have made result in three phenotypes. First are those mutations that result in a limited but measurable effect on MYOA function, like the DSH3 and FS BamHI mutations. The second are those mutations that lead to a complete loss of MYOA function and include the DTH-1-like and the FS KpnI mutants. The last class of mutations are those that have a profound impact on MYOA function. These are the DIQ and FS XhoI mutations.

To our surprise, the DSH3 mutation had a minimal effect on MYOA function. In other proteins, the SH3 and proline-rich domains have been shown to mediate protein-protein interactions (3) and in fact, proline-rich motifs have been shown to directly interact with the SH3 domains (21). In MYOA, however, deletion of the SH3 domain led to nearly wild type growth. Therefore, if SH3 is mediating some protein-protein interaction in our system it is not essential or it is redundant with another

**TABLE IV**

| Time (h) | Spore | Single germ tube | Multiple germ tubes | Branched mycelium |
|----------|-------|------------------|---------------------|------------------|
| 5 h      | WT    | 98               | 2                   | 0                |
|          | FSHkOI| 99               | 1                   | 0                |
|          | FS BamHI| 97             | 3                   | 0                |
|          | DIQ   | 100              | 0                   | 0                |
|          | SH3   | 99               | 1                   | 0                |
| 6 h      | WT    | 77               | 23                  | 0                |
|          | FSHkOI| 99               | 1                   | 0                |
|          | FS BamHI| 84            | 15                  | 0                |
|          | DIQ   | 100              | 0                   | 0                |
|          | SH3   | 92               | 8                   | 0                |
| 7 h      | WT    | 25               | 70                  | 0                |
|          | FSHkOI| 98               | 2                   | 0                |
|          | FS BamHI| 20             | 77                  | 3                |
|          | DIQ   | 100              | 0                   | 0                |
|          | SH3   | 56               | 43                  | 1                |
| 8 h      | WT    | 6                | 89                  | 5                |
|          | FSHkOI| 99               | 1                   | 0                |
|          | FS BamHI| 18            | 76                  | 6                |
|          | DIQ   | 89               | 0                   | 0                |
|          | SH3   | 18               | 77                  | 5                |
| 9 h      | WT    | 0                | 93                  | 7                |
|          | FSHkOI| 98               | 2                   | 0                |
|          | FS BamHI| 3             | 90                  | 7                |
|          | DIQ   | 90               | 3                   | 7                |
|          | SH3   | 1                | 94                  | 5                |
| 10 h     | WT    | 0                | 94                  | 5                |
|          | FSHkOI| 98               | 2                   | 0                |
|          | FS BamHI| 1             | 83                  | 16               |
|          | DIQ   | 40               | 5                   | 55               |
|          | SH3   | 0                | 85                  | 15               |
| 11 h     | WT    | 0                | 91                  | 7                |
|          | FSHkOI| 38               | 56                  | 6                |
|          | FS BamHI| 0             | 90                  | 9                |
|          | DIQ   | 1                | 12                  | 78               |
|          | SH3   | 1                | 86                  | 13               |

**FIG. 5.** Growth of CL3 and CL3 transformants on repressing medium (YAG) or nonrepressing medium (glycerol). Expression of MYOA under the control of the alcA promoter can be controlled in the CL3 strain and in its derivatives by the choice of growth medium. Strains were streaked out on MMV-glycerol (A and B) and YAG (C and D) to determine if the mutants produced a functional MYOA protein. FS BamHI and ΔSH3 grow like the wild type MYOA transformant, CL3-WT, while FS XhoI and ΔIQ form tiny colonies. FS KpnI and ΔTH-1-like fail to complement the conditional null of the CL3 strain.

**FIG. 6.** Growth curves for CL3-WT, FS XhoI, FS BamHI, ΔIQ, and ΔSH3. Strains were germinated in liquid YAG and hyphal length was measured as a function of time. Parental strain CL3 and transformed strains FS KpnI and ΔTH-1-like were not included in this experiment because they do not form hyphae.
system that compensates for loss of the SH3 domain. However, removal of the entire proline-rich COOH-terminal domain, in the FS\textit{Xho}I mutant, resulted in a mutant MYOA that retained only limited function. This mutant grew very poorly and displayed abnormal hyphal branching, suggestive of a failure to correctly initiate and maintain polar apical growth. This suggests that in our system, it is the proline-rich domain, and not the SH3 domain that makes the critically important protein-protein interaction. It is possible that the proline-rich and SH3 domains cooperate in mediating a specific protein interaction and that the SH3 domain acts to fine-tune this interaction. These interactions are possibly necessary for MYOA to be properly localized and thus play a significant role in preventing the precocious formation of hyphal branches. We hypothesize that the proline-rich domain plays an important role in maintaining MYOA at the growing hyphal tip and in the mutant there is a failure to maintain MYOA at a single site, leading to the formation of a second site of apical extension.

In addition, the FS\textit{Bam}HI mutant defines the minimal proline-rich region required for MYOA function. The proline-rich domain consists of two parts with the \textit{Bam}HI site residing in between the two motifs. It still remains to be seen whether a corollary to this mutant, namely one that has the second proline-rich motif will be the functional equivalent of the FS\textit{Bam}HI mutant. We hope to define the essential role of the proline-rich domain in MYOA by creating additional mutations in these domains and by identifying their interacting partners.

The \textit{D}IQ mutation affects more cellular structures than the FS\textit{Xho}I mutation. The variety of defects including thickened cell walls, shorter wider hyphal compartments, and multiple germ tubes seen in this mutant is difficult to explain in a simple model. The IQ motifs define the light chain-binding domain in other myosins. The myosin light chains are members of the EF-hand superfamily of proteins (22) and include the calcium-binding protein, CaM. We have shown that CaM is the light chain of MYOA like in many other myosins (23). The

| Strain   | Width (μm) | Length (μm) |
|---------|------------|-------------|
| CL3-WT  | 1.8 ± 0    | 39 ± 5      |
| FS\textit{Bam}HI | 1.8 ± 0    | 39 ± 6      |
| ΔSH3    | 1.8 ± 0    | 39 ± 5      |
| ΔIQ     | 3.9 ± 1.1  | 16 ± 7      |
| FS\textit{Xho}I | 2.1 ± 0.5  | 13.5 ± 7    |

FIG. 7. Differential interference contrast micrographs of the controls and mutants after 8 h at 37 °C. Bar represents 5 μm.

FIG. 8. Hyphal growth phenotypes for FS\textit{Xho}I and ΔIQ mutants compared with the control strain CL3-WT. Phase micrographs were made at intervals during growth in liquid YAG. The time in hours is indicated at the top of each column. Both the FS\textit{Xho}I and ΔIQ mutants germinate at 11 h and produce multiple germ tubes from the same spore simultaneously. In addition, the FS\textit{Xho}I mutant also displays abnormal hyphal branching which produces Y-shaped apical compartments at 14 and 16 h. In contrast, the ΔIQ mutant exhibits aberrant branching at right angles with multiple sites of initiation in a single compartment. Hyphal tips and compartments are also swollen with thickened cell walls. Bar represents 10 μm.
levels of MYOA correlate with the cellular phenotype. When CL3 is grown on minimal glucose medium, the alcA promoter is not fully repressed as it is on yeast extract glucose medium. Under these conditions MYOA is made in limited quantities and the spectrum of cellular phenotypes we see are not identical to those seen in the ΔIQ or the FSXhoI mutants, as one would predict if the mutations were simply leading to a general loss of MYOA activity. Thus, the specific cellular defects we see in each of these mutants are a reflection of how MYOA is working in the hyphae.

Our previous work showed that MYOA was essential for viability and was required for polarized hyphal growth and protein secretion (9). In contrast, in budding yeast Myo5p has been shown to function in endocytosis but deletion of both class I myosin genes MYO3 and MYO5 is not a lethal event (6, 7). Our more recent work has also implicated MYOA in endocytosis in A. nidulans (10). Because of these studies, we also tested all the mutant strains with a variety of agents that perturb growth like the antimicrotubule agent benomyl. We also examined the mutants for defects in nuclear staining and localization (26), protein secretion (9), endocytosis (10, 27), and actin localization and found that they did not differ significantly from the control strain.

MYOA seems to be involved in several aspects of hyphal morphogenesis. It participates in endocytosis, as demonstrated by our studies of mutations at the TEDS site (10). MYOA also functions in septal wall formation, because the ΔIQ mutant shows defects in the positioning and orientation of septa. Additionally, MYOA plays a role in maintaining cell polarity, because the ΔIQ and FSXhoI mutants grown on YAG and the CL3 strain, when grown under conditions of limited MYOA expression (MMV-glucose) produce hyphae with abnormal branching patterns. Furthermore, the FSXhoI mutant can also form a branch in the apical compartment, something never seen in the wild type strain. Finally, MYOA has other roles in hyphal morphogenesis as illustrated by the abnormal hyphae made in the ΔIQ mutant, which produces contorted hyphae and displays swelling at hyphal tips and walls of subapical compartments. Thus, unlike the case in budding yeast where class I myosin activity is not absolutely required for cell growth, class I myosin function in the filamentous fungus A. nidulans is involved in a variety of activities, all of which contribute to the ability of the fungus to grow.

In summary, we have begun to determine in vivo the functional importance of the various domains in the tail region using in-frame deletion and frameshift mutations. Remarkably, the highly conserved SH3 domain could be removed from the protein with only minimal effects on MYOA function. In contrast, loss of the entire COOH-terminal proline-rich domain had a profound impact on MYOA function. Similarly, removal of the CaM-binding IQ domain resulted in a MYOA that had only a limited capacity to support hyphal growth. The observed presence of calcium has also been shown to stimulate the actin-activated ATPase of other class I myosin 2–3-fold in vitro (24). Therefore, it is likely that in vivo, calcium plays a significant role in regulating MYOA and can partially explain the multiple cellular defects seen in the ΔIQ mutant. Additionally, the IQ domain is proposed to play a role in movement along the actin filament, functioning as a lever arm in the swinging cross-bridge model, in which the IQ motifs cause a conformational change in the head leading to a change in step size (25). This model predicts that removal of the IQ domain would lead to a reduced step size and thus a less effective myosin motor. We are currently producing the ΔIQ MYOA in a baculovirus system for in vitro motility assays to test this hypothesis.

One way to explain the spectrum of phenotypes present in these studies is that they simply reflect the levels of functional MYOA present, ranging from a slightly impaired MYOA which leads to a mild phenotype to a severely impaired MYOA resulting in severe growth defects. An alternative to this hypothesis is that the different phenotypes provide us with insights into how the different domains contribute to MYOA function in vivo. Our analysis of the original conditional null mutant strain CL3 supports this alternative view. Since we are able to grow CL3 under a variety of conditions that will determine the amount of MYOA in the fungus, we are able to see how the levels of MYOA correlate with the cellular phenotype.
differences in cellular defects between the FSXhoI and ΔIQ mutations have allowed us to begin determining how the various domains contribute to the overall function of MYOA. We now need to determine how these important domains specifically contribute to the functioning of MYOA. More detailed studies of the effects of these and additional mutations on MYOA localization are currently in progress. In this respect, it is unfortunate that our antibody detects proteins other than MYOA on Western blots precluding its use in immunofluorescence localization studies of the mutant proteins. We are also trying to identify the proteins that MYOA interacts with to better understand how these complexes mediate the various activities of MYOA.

Acknowledgments—We thank all the members of the laboratory for comments on the manuscript and helpful suggestions during the course of these experiments. We also thank Debbie Townley for assistance with figure reproduction.

REFERENCES
1. Hasson, T., and Mooseker, M. S. (1995) Curr. Opin. Cell Biol. 7, 587–594
2. Mermall, V., Post, P. L., and Mooseker, M. S. (1996) Science 270, 527–533
3. Meyer, B. J., and Eck, M. J. (1995) Curr. Biol. 5, 364–367
4. Novak, K. D., Peterson, M. D., Reedy, M. C., and Titus, M. A. (1995) J. Cell Biol. 131, 1205–1221
5. Brown, S. S. (1997) Curr. Opin. Cell Biol. 9, 44–48
6. Goodson, H. V., Anderson, B. L., Warrick, H. M., Pun, I. A., and Spudich, J. A. (1996) J. Cell Biol. 133, 1277–1291
7. Geli, M. I., and Riezman, H. (1996) Science 272, 533–535
8. Baines, I. C., Corigliano-Murphy, A., and Korn, E. D. (1995) J. Cell Biol. 130, 591–603
9. McGoldrick, C. A., Gruver, C., and May, G. S. (1995) J. Cell Biol. 126, 577–587
10. Yamashita, R. A., and May, G. S. (1998) J. Biol. Chem. 273, 14644–14648
11. Durfee, T., Becherer, K., Chen, P.-L., Yeh, S.-H., Yang, Y., Kilburn A. E., Lee W.-H., and Elledge, S. J. (1995) Genes Dev. 7, 555–569
12. Pontecorvo, G., Roper, J. A., Hemmens, C. M., MacDonald, K. D., and Butun, A. W. J. (1993) Adv. Genet. 5, 141–238
13. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51–59
14. Osmani, S. A., May, G. S., and Morris, N. R. (1987) J. Cell Biol. 104, 1495–1504
15. Feinberg, A. P., and Vogelstein, B. (1983) Anal. Biochem. 132, 6–13
16. May, G. S., Gambino, J., Weatherbee, J. A., and Morris, N. R. (1985) J. Cell Biol. 101, 712–719
17. Laemmli, U. K. (1970) Nature 227, 680–685
18. Waring, R. B., May, G. S., and Morris, N. R. (1999) Gene 70, 119–130
19. Wolkow, D. T., Harris, S. D., and Hamer, J. E. (1996) J. Cell Sci. 109, 2179–2188
20. Fiddy, C., and Trinci, A. P. J. (1976) J. Gen. Microbiol. 97, 169–184
21. Feng, S., Chen, J. K., Hongo, Y., Simon, J. A., and Schreiber, S. L. (1994) Science 266, 1241–1247
22. Moseker, M. S., and Cheney, R. E. (1995) Annu. Rev. Cell Dev. Biol. 11, 633–675
23. Houdusse, A., Silver, M., and Cohen, C. (1996) Structure 4, 1475–1490
24. Kalabokis, V. N., Vibert, P., York, M. L., and Szent-Gyorgyi, A. G. (1996) J. Biol. Chem. 271, 26779–26782
25. Uyeda, T. Q., Abramson, P. D., and Spudich, J. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4459–4444
26. Mirabito, P. M., and Morris, N. R. (1993) J. Cell Biol. 120, 959–968
27. Vida, T. A., and Emr, S. D. (1995) J. Cell Biol. 128, 779–792